Loading clinical trials...
Loading clinical trials...
The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates - A Phase II Study
Conditions
Interventions
Pembrolizumab
Locations
5
United States
University of California San Francisco
San Francisco, California, United States
Children's Hospital Boston
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Cincinnati Children's Medical Center
Cincinnati, Ohio, United States
Baylor College of Medicine
Houston, Texas, United States
Start Date
November 1, 2020
Primary Completion Date
January 1, 2027
Completion Date
January 1, 2028
Last Updated
February 24, 2026
NCT07466602
NCT06345508
NCT04380545
NCT07447050
NCT06620302
NCT07410676
Lead Sponsor
Allison O'Neill, MD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions